menu
    • menu

    Company profile for LIB Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LIB Therapeutics was founded in 2015 by Drs. Evan Stein and August Troendle as a private, self-funded company with assets from BMS. The LIB model is totally virtual, highly flexible, and designed to move through all phases of development and regulation as quickly and smoothly as possible. This has enabled LIB to develop and optimize the manufacturing of its lead asset, lerodalcibep (LIB003), complete all preclinical toxicology...
    LIB Therapeutics was founded in 2015 by Drs. Evan Stein and August Troendle as a private, self-funded company with assets from BMS. The LIB model is totally virtual, highly flexible, and designed to move through all phases of development and regulation as quickly and smoothly as possible. This has enabled LIB to develop and optimize the manufacturing of its lead asset, lerodalcibep (LIB003), complete all preclinical toxicology, phase 1, phase 2 dose selection, a 52-week phase 2b trials, and initiate and enroll 7 large global phase 3 trials in under 6 years.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LIB TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5375 Medpace Way Cincinnati, OH 45227-1543
    Telephone
    Telephone
    +1 8003452032
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.libtherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LIB Therapeutics Unveils Late-Breaking Data At 2025 AHA
    LIB Therapeutics Unveils Late-Breaking Data At 2025 AHA

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110544029/en/LIB-Therapeutics-Announces-Results-from-Late-Breaking-Science-Presentation-at-2025-American-Heart-Association-Meeting-in-New-Orleans-November-9-2025

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    LIB Therapeutics Reveals Results at 2025 Atherosclerosis Society
    LIB Therapeutics Reveals Results at 2025 Atherosclerosis Society

    06 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250506664509/en/LIB-Therapeutics-Announces-Key-Results-from-Presentations-at-2025-European-Atherosclerosis-Society-Meeting-in-Glasgow-May-5-6

    BUSINESSWIRE
    06 May 2025
    Share Share
    Lerodalcibep May Help Patients Needing More LDL-C Reduction
    Lerodalcibep May Help Patients Needing More LDL-C Reduction

    04 Mar 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/lerodalcibep-can-be-a-treatment-option-for-patients-requiring-additional-ldl-c-reduction-globaldata/

    EXPRESSPHARMA
    04 Mar 2025
    Share Share
    LIB Therapeutics Announces FDA Acceptance of BLA for Lerodalcibep
    LIB Therapeutics Announces FDA Acceptance of BLA for Lerodalcibep

    10 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250210806330/en

    BUSINESSWIRE
    10 Feb 2025
    Share Share
    LIB’s Lerodalcibep HoFH Phase 3 Study Published in Lancet Diabetes
    LIB’s Lerodalcibep HoFH Phase 3 Study Published in Lancet Diabetes

    27 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250127840137/en

    BUSINESSWIRE
    27 Jan 2025
    Share Share
    LIB Therapeutic Submits BLA for Lerodalcibep to Treat Elevated LDL
    LIB Therapeutic Submits BLA for Lerodalcibep to Treat Elevated LDL

    16 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241216448140/en

    BUSINESSWIRE
    16 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search